Revance Therapeutics, Inc. (RVNC)
| Market Cap | 342.87M |
| Revenue (ttm) | 234.04M |
| Net Income (ttm) | -323.99M |
| Shares Out | 104.22M |
| EPS (ttm) | -3.83 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,636,477 |
| Open | 3.500 |
| Previous Close | 3.570 |
| Day's Range | 3.230 - 3.500 |
| 52-Week Range | 3.230 - 37.980 |
| Beta | 1.09 |
| Analysts | Buy |
| Price Target | 14.00 (+325.53%) |
| Earnings Date | May 7, 2024 |
About RVNC
Revance Therapeutics, Inc., a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company's lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Ph... [Read more]
Financial Performance
In 2023, RVNC's revenue was $234.04 million, an increase of 76.55% compared to the previous year's $132.57 million. Losses were -$323.99 million, -9.10% less than in 2022.
Financial StatementsAnalyst Forecast
According to 9 analysts, the average rating for RVNC stock is "Buy." The 12-month stock price forecast is $14.0, which is an increase of 325.53% from the latest price.
News
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting.
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Pricing of $100 Million Public Offering of Common Stock.
Revance Announces Proposed Public Offering of Common Stock
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Announces Proposed Public Offering of Common Stock.
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update.
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024.
Revance to Participate in Upcoming Investor Conferences
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in Upcoming Investor Conferences.
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®.
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference.
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook.
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update
NASHVILLE--(BUSINESS WIRE)--Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update.
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Revance Therapeutics, Inc. - RVNC
NEW YORK , Nov. 3, 2023 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Revance Therapeutics, Inc. ("Revance" or the "Company") (NASDAQ: RVNC). Such investors are advis...
Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Third Quarter 2023 Financial Results on Wednesday, November 8, 2023.
Revance Provides Corporate Update at Investor Day
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Provides Corporate Update at Investor Day.
Revance to Host Investor Day on September 19, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Host Investor Day on September 19, 2023.
Revance shares gain 8% after FDA approval of cervical dystonia treatment
Shares of Revance Therapeutics Inc. RVNC, -3.81% gained 8% premarket on Monday after the U.S. Food and Drug Administration approved the biotech company's Daxxify injection for treatment of cervical dy...
Revance's Botox rival gets FDA approval for painful neck muscle condition
The U.S. health regulator has approved expanding the use of Revance Therapeutics' Daxxify to treat a painful neck muscle condition, intensifying the anti-wrinkle injection's rivalry with AbbVie's Boto...
U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia
NASHVILLE, Tenn.--(BUSINESS WIRE)--U.S. FDA Approves First Therapeutic Indication for Revance's DAXXIFY® (DaxibotulinumtoxinA-lanm) for Injection for the Treatment of Cervical Dystonia.
Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports Second Quarter 2023 Financial Results, Provides Corporate Update.
Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance to Release Second Quarter 2023 Financial Results on Tuesday, August 8, 2023.
Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Reports First Quarter 2023 Financial Results, Provides Corporate Update.
Revance to Release First Quarter 2023 Financial Results on Tuesday, May 9, 2023
NASHVILLE, Tenn.--(BUSINESS WIRE)--Revance Therapeutics, Inc. (RVNC), today announced that the company will release first quarter 2023 financial results on Tuesday, May 9, 2023, after the close of mar...
Revance Reports Fourth Quarter and Full Year 2022 Financial Results, Provides Corporate Update
Q4 and full year 2022 total revenue of $49.9 million and $132.6 million, a YoY increase of 92% and 70%, respectively.